On Dec. 15, 2017, the share of Omeros Corporation (NASDAQ:OMER) – a bioscience focusing on the innovation and commercialization of drugs to treat complement-mediated diseases, inflammation, and central nervous system disorders – appreciated $0.47 to trade at $19.68 for 3.52% profits (as of 2:47 pm ET). Since we featured the firm in the Integrated BioSci Interview with....More>>>
Media coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable.....More>>>
Puma Biotechnology (NASDAQ:PBYI)’s share price reached a new 52-week high and low on Thursday . The stock traded as low as $50.15 and last traded at $51.15, with a volume of 13342 shares trading hands. The stock had previously closed at $51.45.
PBYI has been the subject of several research analyst reports. Zacks Investment Research upgraded Puma Biotechnology from a “sell”....More>>>
Why do some companies’ shares trade at $100 or more each while others trade at substantially less? There are many factors that contribute to the price of a stock, the most important being the number of shares outstanding. After all, the share price multiplied by the number of shares available determines a company’s market cap, which is the true price at which the market values a company.
Not many companies have monopolies, though some get pretty close. That list includes Russian telecom giantMobile TeleSystems (NYSE:MBT), biotech playerGilead Sciences, Inc.(NASDAQ:GILD), and tobacco makerAltria Group, Inc. (NYSE:MO). Each one has a slightly different virtual monopoly and they clearly have vastly different businesses. But if you are looking for income from seriously entrenched industry....More>>>
What’s the riskiest big biotech stock on the market? According to market research firm EvaluatePharma, it’sCelgene (NASDAQ:CELG).
Many investors have been very bearish about Celgene for months. The company’s once-promising Crohn’s disease drug GED-0301 flopped miserably in a late-stage clinical study in October 2017. Celgene thoroughly embarrassed itself, with the....More>>>
Anika Therapeutics Inc (NASDAQ:ANIK) – First Analysis lowered their FY2019 earnings per share estimates for Anika Therapeutics in a research report issued on Tuesday, June 19th. First Analysis analyst now forecasts that the biotechnology company will post earnings per share of $1.34 for the year, down from their prior estimate of $1.52. First Analysis has a “Equal Weight”....More>>>
Media headlines about RXi Pharmaceuticals (NASDAQ:RXII) have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RXi....More>>>
Shares of Belgian biotech Galapagos (GLPG) have dipped considerably in the past couple months along with general weakness in the biotech sector, potentially offering would-be investors an entry point into the stock. Even after recent price action the stock has still increased by over 50% since my original recommendation in 2016 calling the firm 篓a long term buy in biotech篓.
Teachers Advisors LLC boosted its position in Concert Pharmaceuticals (NASDAQ:CNCE) by 293.9% during the fourth quarter, Holdings Channel reports. The fund owned 135,399 shares of the biotechnology company’s stock after purchasing an additional 101,026 shares during the quarter. Teachers Advisors LLC’s holdings in Concert Pharmaceuticals were worth $3,503,000 at the end of the most....More>>>
Recently, Prothena Corporation (PRTA) announced that it will slash its workforce. This comes about a month after it had reported that it was forced to cut its NEOD001 clinical candidate due to failing two studies for AL amyloydosis. The slashing of its workforce, and prior trial failures does not bode well for the future of this biotech. The cuts were done to refocus the organization towards its....More>>>
Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure.
The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune....More>>>
The Dow Jones Industrial Average came close to hitting 20,000, but fell short again…nearly four weeks after Barron’s wrote about the possibility in a cover story on Dec. 10.
The S&P 500 rose 0.4% to 2,276.98 today, a record high. The Nasdaq Composite, meanwhile, gained 0.6% to 5,521.06, also a record. The Dow Jones Industrial Average advanced 64.51 points,....More>>>
Right now, there’s a major shift underway in the biotech field that’s creating a brand-new $59.2 billion industry. And investors who get in now could be positioning themselves for triple- or even quadruple-digit gains…
That’s why we’re bringing readers one of the best biotech stocks to buy in December 2017, according to Money Morning Director of Technology....More>>>
With the Allergan (AGN)-Pfizer (PFE) merger scuttled by those pesky new Treausry rules on tax inversions, Allergan will have a lot of cash on hand to go shopping. Who will it buy? Citigroup’s Liav Abraham and Yigal Nochomovitz have ideas:
Brendan McDermid /Reuters
Current market dynamics, particularly in the SMID biotech universe, provide a plethora of opportunities for the company....More>>>